TOPLINE: Ustekinumab exhibited higher persistence rates as a second-line therapy than anti–tumour necrosis factor (anti-TNF) treatment in patients with Crohn’s disease. Clinical remission rates with ustekinumab improved progressively, reaching 100% by 5 years. METHODOLOGY: Researchers conducted this retrospective observational study of a prospective database to compare the persistence rates of ustekinumab as a second-line treatment ...
The Center For Mind & Esteem Development, Inc.
A Course In Personal & Professional Development
LoveNow360 for Self, Community & World
Engagement & Empowerment
Marvin Mack, Founder & Creative Direcotr
The Center For Mind & Esteem Development, Inc. A Course In Personal & Professional LoveNow360 for Self, Community & World Engagement & Empowerment Marvin Mack, Founder & Creative Director lovenow360.net
4109716235
personaldevelopment@me.com
Copyright © 2023 lovenow360worldnews. All Rights Reserved
